Functional/JJ
characterization/NN
of/IN
novel/JJ
IL-2/NN
transcriptional/JJ
inhibitors/NNS
./.

IL-2-mediated/JJ
T/NN
cell/NN
proliferation/NN
is/VBZ
a/DT
critical/JJ
early/JJ
event/NN
in/IN
the/DT
inflammatory/JJ
process/NN
./.
=====
Formation/NN
of/IN
the/DT
NFAT-1/NN
transcriptional/JJ
complex/NN
on/IN
the/DT
IL-2/NN
promoter/NN
is/VBZ
essential/JJ
for/IN
IL-2/NN
transcription/NN
./.
=====
Using/VBG
a/DT
cell/NN
line/NN
that/WDT
is/VBZ
stably/RB
transfected/VBN
with/IN
a/DT
trimer/NN
of/IN
the/DT
NFAT-1/NN
regulatory/JJ
element/NN
linked/VBN
to/TO
a/DT
lac-Z/NN
reporter/NN
gene/NN
,/,
we/PRP
screened/VBD
for/IN
inhibitors/NNS
of/IN
NFAT-1-mediated/JJ
beta-galactosidase/NN
activity/NN
./.
=====
WIN/NN
61058/CD
and/CC
WIN/NN
53071/CD
were/VBD
identified/VBN
as/IN
microM/NN
inhibitors/NNS
./.
=====
These/DT
compounds/NNS
also/RB
inhibited/VBD
beta-galactosidase/NN
mRNA/NN
levels/NNS
./.
=====
Similar/JJ
inhibition/NN
of/IN
NFAT-1-mediated/JJ
gene/NN
expression/NN
was/VBD
observed/VBN
in/IN
a/DT
second/JJ
cell/NN
line/NN
,/,
which/WDT
is/VBZ
stably/RB
transfected/VBN
with/IN
NFAT-1/NN
regulatory/JJ
elements/NNS
linked/VBN
to/TO
the/DT
reporter/NN
gene/NN
for/IN
sCD8/NN
./.
=====
At/IN
10/CD
microM/NN
,/,
both/DT
compounds/NNS
inhibited/VBD
IL-2/NN
mRNA/NN
and/CC
protein/NN
levels/NNS
in/IN
the/DT
NFAT-1-linked/JJ
lac-Z/NN
transfectants/NNS
,/,
and/CC
in/IN
human/JJ
lymphocytes/NNS
./.
=====
Both/DT
compounds/NNS
inhibited/VBD
the/DT
mixed/JJ
lymphocyte/NN
reaction/NN
,/,
and/CC
this/DT
inhibition/NN
was/VBD
reversed/VBN
by/IN
exogenous/JJ
IL-2/NN
./.
=====
WIN/NN
53071/CD
inhibited/VBD
IL-2/NN
production/NN
induced/VBN
in/IN
the/DT
calcium-dependent/JJ
PMA/NN
and/CC
ionomycin/NN
pathway/NN
./.
=====
Conversely/RB
,/,
calcium-independent/JJ
anti-CD28/JJ
Ab/NN
and/CC
PMA-induced/JJ
IL-2/NN
production/NN
was/VBD
resistant/JJ
./.
=====
Both/DT
compounds/NNS
altered/VBD
the/DT
NFAT-1/NN
transcriptional/JJ
complex/NN
,/,
causing/VBG
its/PRP$
retarded/VBN
mobility/NN
on/IN
gels/NNS
./.
=====
By/IN
these/DT
functional/JJ
criteria/NNS
,/,
we/PRP
believe/VBP
we/PRP
have/VBP
identified/VBN
two/CD
structurally/RB
distinct/JJ
,/,
novel/JJ
inhibitors/NNS
of/IN
NFAT-1-mediated/JJ
transcription/NN
./.